Browse by author
Lookup NU author(s): Dr Gordon Strathdee
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Mounting evidence suggests that aberrant methylation of CpG islands is a major pathway leading to the inactivation of tumor suppressor genes and the development of cancer. Recent studies on colorectal and gastric cancer have defined a CpG island methylator phenotype (CIMP), which involves the targeting of multiple genes by promoter hypermethylation. To determine the role of methylation in ovarian cancer, we have investigated the methylation status of 93 primary ovarian tumors at ten loci using methylation-specific polymerase chain reaction (MSP). Seven of the loci (BRCA1, HIC1, MINT25, MINT31, MLH1, p73 and hTR) were found to be methylated in a significant proportion of the ovarian tumors, and methylation of at least one of these was found in the majority (71%) of samples. Although concurrent methylation of multiple genes was commonly seen, this did not seem to be due to a single CIMP phenotype. Instead the results suggest the presence of at least three groups of tumors, two CIMP-positive groups, each susceptible to methylation of a different subset of genes, and a further group of tumors not susceptible to CpG island methylation, at least at the loci studied.
Author(s): Strathdee G; Appleton K; Illand M; Millan DWM; Sargent J; Paul J; Brown R
Publication type: Article
Publication status: Published
Journal: American Journal of Pathology
Year: 2001
Volume: 158
Issue: 3
Pages: 1121-1127
Print publication date: 21/12/2010
ISSN (print): 0002-9440
ISSN (electronic): 1525-2191
Publisher: Elsevier Inc.
URL: http://dx.doi.org/10.1016/S0002-9440(10)64059-X
DOI: 10.1016/S0002-9440(10)64059-X
Altmetrics provided by Altmetric
